

Corporate Action Notice

December 15, 2016

Rights Offering

Nabriva Therapeutics

DR CUSIP: 62957M104

DR ISIN: US62957M1045

DR Ticker Symbol: NBRV

Ratio (DRs: Underlying Shares): 10:1

The final rates for the Nabriva Therapeutics AG American Depositary Shares ("ADSs") rights offering that expired on December 12, 2016 have been set.

The final details of the offer are as follows:

Euro Subscription Price: EUR4.014 per ADS

Foreign Exchange Rate: 1.0646 USD for each Euro

ADS Subscription Price: \$4.273304 per ADS

Depository Issuance Fee: \$0.050000 per ADS

Total: \$4.323304 per ADS

ADR holders will receive a refund of \$0.356696 per ADS subscribed from their initial deposit amount of \$4.68 per ADS.

Subject to receipt of the underlying shares in Austria, BNY Mellon expects to issue the new ADSs on or about December 19, 2016.

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

NEW YORK

Ravi Davis

Richard J Maehr

+ 1 212 815 2267

addrdesk@bnymellon.com

LONDON

Jacek Jankowski

Vice President

+ 44 207 163 7427

jacek.jankowski@bnymellon.com

BNY Mellon is providing this information for general informational purposes only and does not warrant or guarantee the accuracy, timeliness or completeness of this information. BNY Mellon does not undertake any obligation to update or amend this information. BNY Mellon provides no advice, recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. BNY Mellon collects fees from Depositary Receipt ("DR") holders pursuant to the terms and conditions of the DRs. BNY Mellon may make payments to sponsored DR issuers to reimburse and /or share revenue from the fees collected from DR holders, or waive fees and expenses for services provided. BNY Mellon may pay a rebate to brokers in connection with unsponsored DR issuances. BNY Mellon may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions. BNY Mellon may execute DR foreign currency transactions itself or through its affiliates and in such cases it acts as principal counterparty and not as agent, advisor, broker or fiduciary. BNY Mellon has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY Mellon earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account. The methodology used by BNY Mellon to determine DR conversion rates is available to registered Owners upon request or at https://www.adrbnymellon.com/us/en/news-and-publications/dr-issuers/asset_upload_file49220_197380.pdf. Depositary Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of, and are not guaranteed by BNY Mellon, and are subject to investment risks.



BNY MELLON